SPAC Presentation

Procaps at a Glance Foundations for Growth by a Tested Business Strategy 1 3 State-of-the-art Manufacturing Capabilities Providing Innovative Delivery Technologies ■ I H Corporate culture focused on innovation and R&D I First FDA-approved Rx pharmaceutical plant in South America Leading global softgel player (#1 in LatAm in terms of volume of softgel production capacity¹) 62% of sales are linked to Procaps' own technologies and intellectual property Regional Footprint with Vertical and Horizontal Integration and Global Reach Maximize Growth Opportunities and Synergies 6 manufacturing facilities across the region including the only hormonal softgel plant in Latin America Products sold & distributed in ~50 markets Source: Procaps, QYR Research Note: (1) QYR Research market report as of 2020 PROCAPS GROUP I I Proprietary Rx and OTC Product Portfolio Leveraged on Procaps' Delivery Systems ■ ■ PROCAPS ■ ▪ 3 successful acquisitions throughout Latin America 99% of product portfolio is proprietary with a focus on high-growth therapeutic areas ▪ Innovative delivery mechanisms allow Procaps to transform Branded Generics into differentiated products Focus on Organic and Inorganic Growth with Increased Margin Expansion Focused on premium markets without competing on price GROUP 1 brand acquired by Procaps in the last 3 years 1 in-house business incubation, Diabetrics (2015) Further development of e-Health segment .:: 2 4 12

View entire presentation